Expression of farnesyltransferase in primary liver cancer
- Author:
- No author available
- Journal Title:
- Chinese Medical Journal
- Issue:
- 14
- DOI:
- 10.3760/cma.j.issn.0366-6999.2012.14.005
- Key Word:
- primary liver cancer;farnesyltransferase;fluorescent quantitative-polymerase chain reaction
Abstract： Background Primary liver cancer (PLC) is a common malignant tumor.Over the past decade,although farnesyltransferase (FTase) has emerged as a significant target for anticancer therapies and has become a hotspot of cancer research,its exact mechanism of action remains unknown.The aim of this study was to investigate the expression of FTase in PLC and its role in the development of PLC.Methods Expression of FTase was detected by real-time fluorescent quantitative-polymerase chain reaction (FQ-PCR)in cancer and surrounding normal tissues from 32 patients with PLC.Results Expression of FTase mRNA in PLC was significantly higher than that in normal hepatic tissues (P ＜0.001).Overexpression of FTase was as high as 87.5％.The positive rate for FTase mRNA in the high tendency to metastatic recurrence group was obviously higher than that in the low tendency to metastatic recurrence group (P=0.02).The positive rate for FTase mRNA in patients with metastatic recurrence during postoperative follow-up was also significantly higher than that in those without metastatic recurrence (P=0.01).Conclusions The level of FTase mRNA expression in cancer tissues is much higher than in normal tissues.FTase may play an important role in the genesis and development of PLC and may be one of the reliable markers for the metastatic activity gained by liver tumor cells.FTase could be used clinically in predicting metastatic recurrence of PLC.
- [1]Khan, Abdul Hafeez,Prakash, Alok,Kumar, Dinesh,etc.Virtual screening and pharmacophore studies for ftase inhibitors using Indian plant anticancer compounds database.[J].2010,5(2).
- [2]Jun-Min, Zhou,Xiao-Feng, Zhu,Qi-Chao, Pan,etc.Manumycin inhibits cell proliferation and the Ras signal transduction pathway in human hepatocellular carcinoma cells.[J].2003,11.
- [3]Agrawal AG,Somani RR.Farnesyltransferase inhibitor as anticancer agent.[J].2009,9(6).
- [4]Kauh J,Chanel Vos C,Escuin D,etc.Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.[J].2011,117(17).
- [5]Dalin, M,Yu, HM,Yang, SH,etc.Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer[J].2010,107(14).
- [6]Siegel Lakhai WS,Crul M,De Porre P,etc.Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function.[J].2006,24(28).
- [7]T, Nagase,S, Kawata,H, Nakajima,etc.Effect of farnesyltransferase overexpression on cell growth and transformation.[J].1999,80.
- [8]Sousa SF,Fernandes PA,Ramos MJ.Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem.[J].2008,15(15).
- [9].Ras-MAPK pathway as a therapeutic target in cancer--emphasis on bladder cancer.[J].2009,4(2).
- [10]Bidaud A,Grise F,Moreau V.Rho GTPases in hepatocellular carcinoma.[J].2009,1795(2).
- [11]Montero J,Morales A,Llacuna L,etc.Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma.[J].2008,68(13).
- [12]Livak KJ,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.[J].2001,25(4).
- [13]Yang T,Yu WF,Lu JH,etc.A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort.[J].2011,137(5).
- [14]Kawasaki K,Watabe T,Sase H,etc.Ras signaling directs endothelial specification of VEGFR2(+) vascular progenitor cells[J].2008,181(1).
- [15]John M, Luk,Angela M, Liu.Proteomics of hepatocellular carcinoma in Chinese patients.[J].2011,15(5).